Although lymphoma is one of the most common types of blood cancer, it has a rare subtype for which no effective treatment regimens are known. For the first time, Nagoya University researchers and colleagues in Japan have conducted clinical trials for a new treatment protocol and report it to be quite promising.
- UT southwestern levels the playing field for testicular cancer patients
- Addition of sintilimab to pemetrexed and platinum improved progression-free survival
- Phase 3 eXalt3 study shows significantly longer progression-free survival
- checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab
- Scientists discover curious clues in the war between cf bacteria